Search

Exelixis Inc

Geschlossen

BrancheGesundheitswesen

58.9 -0.3

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

58.76

Max

59.14

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.6M

212M

Verkäufe

18M

629M

KGV

Branchendurchschnitt

17.129

56.659

EPS

0.82

Gewinnspanne

33.729

Angestellte

1,077

EBITDA

-12M

263M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-12.01% downside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-301M

14B

Vorheriger Eröffnungskurs

59.2

Vorheriger Schlusskurs

58.9

Nachrichtenstimmung

By Acuity

50%

50%

131 / 339 Ranking in Healthcare

Exelixis Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Sept. 2026, 20:07 UTC

Exelixis Inc is advancing during Thursday's session, maintaining upward momentum since Wednesday. No specific news was identified to explain the price movement.

2. Sept. 2026, 23:56 UTC

Exelixis Inc shares are higher in after-market trading, though no specific news was identified. The broader market reacted to weaker ADP payroll data.

1. Sept. 2026, 23:06 UTC

Exelixis Inc. shares are lower in after-market hours, with no specific news identified for the decline amid broader market concerns.

31. Aug. 2026, 22:16 UTC

Exelixis shares are higher in after-market hours, rebounding from a slight dip earlier. This follows broader market reactions to Federal Reserve comments on inflation.

28. Aug. 2026, 23:01 UTC

Exelixis Inc shares are lower in after-market hours, continuing a trend of declines amid rising interest rate hike expectations affecting the biotechnology sector.

27. Aug. 2026, 20:07 UTC

Exelixis Inc shares are trading lower amid broader market declines. The cumulative return has reached a low point, with no specific news driving the movement.

26. Aug. 2026, 23:01 UTC

Exelixis Inc's shares are higher in after-market trading, reaching a high of 0.73% above Wednesday's close and 5.12% above its 20-day moving average.

25. Aug. 2026, 19:45 UTC

Exelixis Inc is trading higher amid a favorable market backdrop of declining crude oil prices and decreasing Treasury yields, continuing its upward momentum.

24. Aug. 2026, 19:36 UTC

Exelixis Inc. shares are modestly higher since Friday's close, trading within the middle of their one-month range and above the 20-day moving average.

21. Aug. 2026, 20:06 UTC

Exelixis Inc shares are higher today, continuing a trend since Thursday's close. Broader biotechnology sector gains may be contributing to the movement.

20. Aug. 2026, 23:36 UTC

Exelixis Inc's shares are higher in after-market trading, reflecting notable strength despite no specific news to explain the price action.

19. Aug. 2026, 19:36 UTC

News

BMO Capital initiated coverage on Exelixis Inc with a Market Perform rating and a price target of $54. Shares are trading higher today.

18. Aug. 2026, 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

13. Aug. 2026, 19:46 UTC

Exelixis Inc's shares are higher Thursday, supported by positive investor sentiment despite a slight pullback from earlier gains. Initial jobless claims rose to 209k.

12. Aug. 2026, 19:51 UTC

News

Exelixis Inc shares are lower amid an investigation for potential securities law violations and a revenue shortfall of $628.7 million in Q2.

11. Aug. 2026, 23:51 UTC

Exelixis Inc shares are lower in after-market hours, continuing a downward trend since Tuesday's close amid notable volatility and market anticipation of the CPI report.

10. Aug. 2026, 23:01 UTC

News

Exelixis shares are lower in after-market trading amid scrutiny over a potential securities fraud investigation and lowered full-year revenue guidance.

8. Aug. 2026, 00:01 UTC

Exelixis Inc shares are trading lower in after-market hours, amid weak overall market conditions and unusual trading patterns.

7. Aug. 2026, 21:01 UTC

Exelixis Inc shares are lower in after-market trading, reflecting notable weakness and remaining below the 20-day moving average. No specific news was identified.

6. Aug. 2026, 23:31 UTC

Exelixis Inc's shares are higher in after-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

5. Aug. 2026, 23:02 UTC

News

Exelixis Inc. shares are lower in after-market trading following second-quarter results that missed revenue expectations and a cut to full-year guidance.

4. Aug. 2026, 19:16 UTC

Exelixis Inc shares are higher today, reaching a peak above Monday's close. The broader market is supported by a drop in crude oil prices.

3. Aug. 2026, 23:02 UTC

Exelixis Inc shares are lower in after-market trading, continuing a decline since Monday's close amid no specific news to explain the movement.

31. Juli 2026, 23:36 UTC

Exelixis Inc shares are lower in after-market trading, influenced by broader market weakness amid a decline in Apple shares following disappointing guidance.

30. Juli 2026, 17:56 UTC

Exelixis shares are higher during Thursday's session, gradually improving from an early dip. No specific company news was identified to explain the movement.

29. Juli 2026, 19:37 UTC

Exelixis Inc. shares are trading lower today amid high volume and broader market dynamics, including a significant surge in oil prices raising inflation concerns.

28. Juli 2026, 20:06 UTC

Exelixis Inc is trading higher amid a strong Biotechnology sector. The stock remains above its 20-day moving average, indicating market strength.

27. Juli 2026, 18:46 UTC

Exelixis Inc shares are higher today, reflecting broader market trends amid a notable decline in crude oil prices. The stock peaked earlier in the session.

24. Juli 2026, 19:46 UTC

Exelixis Inc shares are lower today, continuing a decline since Thursday. Broader market volatility is influenced by fluctuations in oil prices and U.S. tariffs.

22. Juli 2026, 21:26 UTC

News

Exelixis Inc will release its Q2 2026 financial results on August 5. Shares are trading higher after the announcement, reflecting positive investor sentiment.

Peer-Vergleich

Kursveränderung

Exelixis Inc Prognose

Kursziel

By TipRanks

-12.01% Nachteil

12-Monats-Prognose

Durchschnitt 51.92 USD  -12.01%

Hoch 64 USD

Tief 41 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Exelixis Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

15 ratings

4

Buy

10

Halten

1

Sell

Stimmung

By Acuity

131 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
help-icon Live chat